The ENHANCE Project Toolkit
Mobile Health Strategies to Support Longitudinal Engagement in Comprehensive, Community-based Prevention Services for People Who Use Drugs (Aim 3)
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
As a pilot study, this study is not designed to rigorously evaluate the effect of the intervention (i.e., health-related biomedical or behavioral outcome) on participants. Rather, the sample size will allow determination of feasibility, acceptability, appropriateness, and secondarily, will allow quantification of preliminary effect size to aid in future trial planning. After enrolling in the study, participants will receive a mobile phone with an unlimited data plan. After receiving the phone, participants will receive a brief orientation to a bundle of phone and internet-based overdose prevention tools. This includes overdose crisis hotlines, mail-order overdose prevention supplies, and a mobile health app that has been adapted for people who use drugs to support self-determined motivation for reaching goals through educational content, social engagement, and peer-to-peer support. Each month for 6 months, participants will also complete a 20-30 minute survey evaluating the primary and secondary outcomes (described below) and use of each phone and internet-based tool that is part of the enhanced harm reduction bundle. 25 participants will also be invited to complete a 45-60 minute semi-structured in-depth interview about their experience participating in the study and use of the phone- and internet-based tools. Primary analyses will seek to describe the feasibility, acceptability, and appropriateness of the overdose prevention service model. Secondarily, changes in overdose risk behaviors and experiences over the 6-month study period relative to baseline will be analyzed.
Primary Objective: to evaluate feasibility, appropriateness, and acceptability of an enhanced harm reduction service model incorporating internet and/or mobile health tools to reduce overdose risk for people who use opioid and/or stimulant drugs.
Secondary Objective: to understand overdose risk behaviors before and after the intervention.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Research Team
- Puhelinnumero: (608) 572-3514
- Sähköposti: enhance@medicine.wisc.edu
Opiskelupaikat
-
-
Wisconsin
-
Madison, Wisconsin, Yhdysvallat, 53792
- Rekrytointi
- UW School of Medicine and Public Health
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria (Pilot Participant):
- Be at least 18 years old
- Be able to read and write in English
Report drug use in the past 30 days, defined as
- Any use of illicit stimulants, opioids, OR
- Use of prescription opioids by a route other than "by mouth/swallowed"
- Additionally report recent drug use of at least twice in the past 7 days
Have NOT used any of the following harm reduction services in the past 6 months:
- In-person community-based prevention services for people who use drugs
- Overdose crisis hotlines
- Online mail-order prevention supply delivery
- Apps for supporting addiction treatment or recovery
Inclusion Criteria (Peer Mentor Participant):
- Be at least 18 years old
- Be able to read and write in English
- Have served as a member of the existing Community Leadership Team.
Exclusion Criteria:
- Are under the age of 18
- Have impaired decision making capacity at the time of screening
Do not have the ability to participate in screening and enrollment activities in any one of the following ways:
- Traveling to their nearest participating Vivent Health health center
- Coordinating a visit with the Vivent Health harm reduction mobile unit
- Accessing and completing the online screening survey on a personal wifi/internet enabled device
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Laitteen toteutettavuus
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Pilot Participants
People who use opioid and/or stimulant drugs and are disconnected from harm reduction services.
|
Mobile health app, bundled with other harm reduction internet and phone resources
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Acceptability of Intervention Measure (AIM)
Aikaikkuna: up to 6 months
|
The Acceptability of Intervention Measure (AIM) measures intervention acceptability with 4 items ranked on a 5-point Likert-type scale.
Participants will be asked the 4-item questionnaire for each tool offered in the bundle (3).
Scores are averaged across the measure for each tool and subsequently scores for individual tools will be summed to generate a composite acceptability score of the program.
Scores can range from 3-15, with higher scores meaning higher acceptability of the intervention
|
up to 6 months
|
|
Intervention Appropriateness Measure (IAM)
Aikaikkuna: up to 6 months
|
The Intervention Appropriateness Measure (IAM) measures intervention appropriateness with 4 items ranked on a 5-point Likert-type scale.
Participants will be asked the 4-item questionnaire for each tool offered in the bundle (3).
Scores are averaged across the measure for each tool and subsequently scores for individual tools will be summed to generate a composite appropriateness score of the program.
Scores can range from 3-15, with higher scores meaning higher appropriateness of the intervention.
|
up to 6 months
|
|
Feasibility of Intervention Measure (FIM)
Aikaikkuna: up to 6 months
|
The Feasibility of Intervention Measure (FIM) measures intervention feasibility with 4 items ranked on a 5-point Likert-type scale.
Participants will be asked the 4-item questionnaire for each tool offered in the bundle (3).
Scores are averaged across the measure for each tool and subsequently scores for individual tools will be summed to generate a composite feasibility score of the program.
Scores can range from 3-15, with higher scores meaning higher feasibility of the intervention.
|
up to 6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in the Number of Risk Days from baseline to 6 months
Aikaikkuna: baseline, 6 months
|
This data will be collected using the Overdose Risk Behavior Scale (ORBS) instrument which provides a comprehensive index of proximal opioid-related overdose risks.
At baseline and study completion, participants will complete the ORBS assessment.
The ORBS assessment will be administered to assess the potential effect of the intervention on the frequency of overdose risk behaviors.
The average change in the self reported risk days on this instrument from baseline to six months will be reported as the outcome.
|
baseline, 6 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Ryan Westergaard, MD, PhD, MPH, UW School of Medicine and Public Health
- Päätutkija: Rachel Gicquelais, PhD, MPH, UW School of Medicine and Public Health
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2026-0408
- Protocol Version 3/13/26 (Muu tunniste: UW- Madison)
- R01DA057645-02 (Yhdysvaltain NIH-apuraha/sopimus)
- SMPH | Population Health (Muu tunniste: UW Madison)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .